CRBP - Corbus Pharmaceuticals Holdings, Inc.
收市後：
| 前收市價 | 8.87 |
| 開市 | 9.15 |
| 買盤 | 9.36 x 1000 |
| 賣出價 | 9.60 x 2900 |
| 今日波幅 | 9.15 - 9.89 |
| 52 週波幅 | 2.11 - 13.17 |
| 成交量 | |
| 平均成交量 | 444,512 |
| 市值 | 39.917M |
| Beta 值 (5 年，每月) | 2.43 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -10.85 |
| 業績公佈日 | 2023年8月07日 - 2023年8月11日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 71.00 |
BenzingaCorbus Pharma Expands Precision Oncology Pipeline With Addition Of Clinical-Stage Antibody Drug Conjugate
Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) entered into an exclusive licensing agreement with CSPC Megalith Biopharmaceutical Co Ltd, a subsidiary of CSPC Pharmaceutical Group Limited, for the development and commercialization of CRB-701 (SYS6002), an antibody-drug conjugate targeting Nectin-4. The agreement covers exclusive commercialization rights to CRB-701 in the U.S., Canada, the European Union, the U.K., and Australia. The FDA has cleared the IND for CRB-701. CSPC is currently inve
Insider Monkey15 Best High Volume Penny Stocks to Buy Now
In this article, we discuss the 15 best high volume penny stocks to buy now. If you want to read about some more high volume penny stocks, go directly to 5 Best High Volume Penny Stocks to Buy Now. Penny stocks had become an important indicator of the overall health of the stock market in […]